Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717567 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2UCHL1CHRM2CHRM1 | |
| Ammonia Solution, Strong SCHEMBL28112854 | 0.98 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2UCHL1CHRM2CHRM1 | |
| SCHEMBL721105 | 0.88 | PTPN1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL19566140 | 0.88 | NPC1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL717566 | 0.88 | PTPN1 (0.38) | HSD17B10UCHL1CHRM2CHRM1CHRM3 | |
| SCHEMBL85511 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL204965 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL204966 | 0.86 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL22543468 | 0.85 | PTPN1 (0.46) | HSD17B10UCHL1NPC1PTPN1 | |
| SCHEMBL10058225 | 0.85 | PTPN1 (0.46) | HSD17B10UCHL1NPC1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| CN-101258157-A | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| EP-1891078-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125974-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131444-A1 | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity | AAAS, AMPD2, AMPD3 | HSD17B10 4776/4885SMN1; SMN2 4388/4885UCHL1 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.